Page URL:

Cash boost for personalised medicines

23 June 2004
By BioNews
Appeared in BioNews 264

Research into pharmacogenetics- the use of genetic tests to match medicines to a person's genetic make-up - is to receive £4 million of funding, Health Minister Lord Warner announced last week. The cash will go to six different research projects, which include studies on medicines used to prevent blood clots, epilepsy drugs and a test to identify people at risk of having a fatal reaction to general anaesthetics.

'Whilst research in this area is still in its early stages, pharmacogenetics has enormous potential to improve the effectiveness of some treatments that patients receive, and more importantly could save lives by identifying those patients who, because of their genetic make-up, are likely to react badly to certain medicines', said Lord Warner.

The new funding forms part of the UK government's strategy to integrate genetics into routine healthcare, outlined in the White Paper published in June 2003. Many scientists feel that personalised medicines will revolutionise medical care in the future, leading to doctors prescribing 'the right drug, for the right patient, given at the right dose'. However, only a handful of the genetic variations linked to adverse reactions or a reduced response to a particular drug have so far been identified.

Some of the funding will go to scientists based at St James' University Hospital in Leeds, who are aiming to develop a new screening test to detect people at risk of developing malignant hyperthermia, a potentially fatal reaction to general anaesthetic drugs. Another project to benefit is one investigating the genetic basis of the side effects triggered by the anti-inflammatory drug azathioprine, being carried out at Salford Royal Hospital.

Scientists at the University of Liverpool will carry out research into adverse reactions to the anti-blood-clotting drug Warfarin, while a team at the Walton Centre for Neurology and Neurosurgery aims to develop a test to predict a person's response to the epilepsy drug Clobazam. University of Liverpool researchers will look at the genetic factors that trigger liver damage after taking penicillin and anti-tuberculosis medicines. The sixth project to receive funding is one investigating the genes that cause sensitivity to anthracyclines, which are very effective cancer drugs, but can cause heart damage in susceptible individuals.

£4 million of funding into pharmacogenetics |  22 June 2004
20 June 2011 - by Ruth Pidsley 
US scientists have reported possibly the first example of using one person's genetic sequence to refine a diagnosis and provide personalised medical treatment. Whole-genome sequencing (WGS) helped pinpoint defects in the DNA of 14-year-old fraternal twins Noah and Alexis Beery causing their rare neurological condition, dopamine-responsive dystonia (DRD)...
10 October 2005 - by BioNews 
Japanese companies have built a desk-top machine that allows doctors to check their patients' DNA before writing a prescription, the journal Nature reports. The device, which they say will be on sale for five million yen (£25,000) in a year's time, uses a single drop of blood and delivers results...
22 September 2005 - by BioNews 
The UK's Royal Society has published a report on the potential of pharmacogenetics - drug treatments tailored to a person's genetic make-up - following a year-long investigation into the subject. It concludes that although 'personalised medicines' have a promising future, it will be at least another 15-20 years before their use...
21 September 2004 - by BioNews 
The UK's Royal Society is launching a year-long investigation into the potential of pharmacogenetics: drug treatments tailored to a person's genetic make-up. The study, headed by geneticist Sir David Weatherall, will look at when and if 'personalised medicine' will become a reality. It will also assess whether healthcare providers in...
10 September 2004 - by BioNews 
A genetic test that helps predict how people will react to certain medicines has been approved for sale in the European Union, Swiss firm Roche Diagnostics has announced. The test, called the AmpliChip CYP450, detects variations in two genes that make key liver enzymes. Variations in the activity of these...
18 June 2004 - by BioNews 
Genes can affect a person's response to statins, drugs used to lower blood cholesterol levels, say US researchers. Researchers at the Brigham and Women's Hospital in Boston say their study shows that knowledge about the interaction between genes and drugs is growing 'in leaps and bounds'. Their findings, published in...
4 May 2004 - by BioNews 
Targeted cancer treatments, based on genetic profiling results, could soon become a reality. A team lead by researchers at the Dana-Farber Cancer Institute, in the US, has found that only lung tumours with a particular gene mutation are likely to respond to treatment with the drug gefitinib. The work is...
25 September 2003 - by BioNews 
The UK's Nuffield Council on Bioethics has published a report on the ethical and policy issues surrounding pharmacogenetics: the use of tests to match medicines to a person's genetic make-up. It concludes that although such tests may significantly improve the quality of patient care, it is still unclear how quickly...
27 June 2003 - by BioNews 
The UK government unveiled its plans for genetics in the National Health Service (NHS) last week, in the form of a white paper entitled 'Our inheritance, our future - realising the potential of genetics in the NHS'. The document lays out new measures for strengthening existing genetics services, and for incorporating...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.